Antonio Pato-Pato
The direct costs associated with epilepsy management were evaluated. Patients and methods: Prospective, observational study conducted over 6 months in patients over 14 years of age with epilepsy. Patients with concomitant diseases that could influence epilepsy were excluded. The direct medical costs included: number of neurology, primary care and A&E visits; number and type of diagnostic tests; days of hospitalisation; and treatment administered for epilepsy. The non-medical direct costs were associated with transport to and from hospital and the use of psychological and social support. Result: 171 patients were analysed. The mean cost of anti-epileptic drugs was 513.6 €. The mean cost of medical visits and hospitalisations was 322.3 €. The cost of investigations per patient was 174.8 €. The mean total direct medical costs were 1,010.4 €, with the drugs being the most significant item. The mean non-medical direct costs were 45 €. Average direct costs totalled 1,055.2 € per patient, and medical costs were the most significant item. Conclusions: the use of anti-epileptic drugs is a heavy burden for the health service. The expenditure on medical visits, hospitalisations and investigations in epilepsy is higher than the health service’s mean annual expenditure per patient.
English 
Spanish 
Chinese 
Russian 
French 
Japanese 
Portuguese 
Hindi